Navigation Links
Everolimus slows disease progression in advanced papillary kidney cancer patients
Date:9/27/2013

The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease, according to research to be presented today (Sunday) at the 2013 European Cancer Congress (ECC2013) [1].

Dr Bernard Escudier, Head of the French Group of Immunotherapy and chairman of the Genitourinary tumour board at the Institut Gustave Roussy in Villejuif, France will say: "Our results showed that for 59% of patients who received everolimus as their first-line treatment, their disease did not get worse and remained stable. These findings are important and indicate that more than half of these cancer patients are getting some kind of benefit from everolimus treatment.

"Advanced papillary kidney cancer is a very difficult cancer to treat, and because there is no standard of care, there is disagreement amongst experts regarding the best treatment option for these patients. Our clinical findings are encouraging and suggest that everolimus may represent a new treatment option."

Papillary kidney cancer is the second most frequent type of kidney cancer and accounts for approximately 15% of all kidney cancer cases; it is five times more common in men than in women. When the cancer is confined to one location, surgical removal is usually associated with an excellent prognosis. However, when it spreads to other parts of the body, therapies are ineffective. There are two types of papillary cancer, based on cell appearance (histology), known as type I and type II. Type I are more common and grow slowly, whereas type II papillary kidney cancers are much more aggressive and have a poor prognosis.

Everolimus is an anti-cancer drug known as an mTOR inhibitor; mTOR stands for "mammalian target of rapamycin" and it is a protein that regulates vital cell growth processes, including cell metabolism, growth and p
'/>"/>

Contact: Kay Roche
kay@rochewriting.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Thwarting protein production slows cancer cells malignant march
2. Aging - Daily Sunscreen Use Slows the Visible Signs of Aging Skin
3. Skin Care – Sunscreen Slows Skin Aging
4. Skin Care – Daily Sunscreen Use Slows Skin Aging
5. Scientists discover how rapamycin slows cell growth
6. Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency
7. Low-protein diet slows Alzheimers in mice
8. Newly approved oral medication slows rheumatoid arthritis joint damage
9. Active lifestyle boosts brain structure and slows Alzheimer’s disease
10. Mesothelioma drug slows disease progression in patients with an inactive NF2 gene
11. Mild HIV type slows development of AIDS and makes new preventive treatments possible
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... is helping people perform better in and out of the ... and memory has caught the attention of Shane Michaels, prompting ... day-to-day grind, fatigue is the reason most people simply just ... whether that means staying focused at work, getting the motivation ...
(Date:9/30/2014)... For most families, fall means back-to-school ... patch or annual festival. For millions of children, fall ... the respiratory infection Enterovirus D68. , While symptoms ... percentage – especially children with weakened immune systems – ... Enterovirus is prompting hospitals across the country to enact ...
(Date:9/30/2014)... Tampa, FL (PRWEB) September 30, 2014 ... doors to two new clinics in Nashville, Tennessee. RMS ... Sleep Apnea Institute, and the expansion of a new ... the introduction of the Sleep Apnea Institute to Nashville, ... that suffer from sleep apnea: both diagnosed and undiagnosed. ...
(Date:9/30/2014)... 30, 2014 Two revolutionary procedures now being ... of gum disease a far less painful and far ... “If you’ve ever felt electric shock waves surge through your ... cold beverage, it’s possible you already know the impact of ... a general dentist in West Palm Beach, and a Fellow ...
(Date:9/30/2014)... (Sept. 30, 2014) Levothyroxine is considered the gold ... a new review of therapies for the condition ... altered that assessment, say a team of investigators.,1Their analysis, ... Thyroid , finds insufficient consistent data exist to ... generic, or sold under various trade names, such as ...
Breaking Medicine News(10 mins):Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:As Hospitals Combat Enterovirus Outbreaks, Patients and Families Turn to “Virtual Visits” with CaringBridge 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2
... Plan Participation , , FALLS ... plan executives expect the current economic crisis to have a ... to a survey released today by CSC (NYSE: ... the Financial Crisis." While few expect immediate changes in enrollment ...
... (December 16, 2008) The Life Sciences Discovery ... Four Washington State-based research organizations will receive life ... The newly-funded health research initiatives will focus on ... resuscitation technology, improving the delivery of mental health ...
... a neurological disorder characterized by involuntary abnormal muscle constrictions. ... but the mechanism of abnormal muscle constrictions has not ... Prof Atsushi Nambu and Dr Satomi Chiken of National ... Pullanipally Shashidharan of Mt Sinai School of Medicine in ...
... VirtualHealth,Technologies, Inc. (OTC Bulletin Board: VHGI) the owners ... announced today,that it has appointed Anthony Bocchichio to its ... Mr. Bocchichio has over 37 years of experience in ... the Drug Enforcement Agency. He served,as both Assistant Special ...
... Cadence Pharmaceuticals, Inc.,(Nasdaq: CADX ) today ... III clinical trial of Acetavance(TM), the company,s intravenous,formulation ... following,abdominal laparoscopic surgery. Study 304 successfully met ... summed pain intensity,differences from baseline over 24 hours ...
... Guidenz , the medical information business unit of Cerebrio, ... OMC ), and MedLink International, Inc. (OTC Bulletin Board: MLKNA), ... and services that ease the accessibility of physicians and patients ... agreement to develop and market a suite of unique information ...
Cached Medicine News:Health News:Health Plan Executives Foresee Continued Decline in Small Business Enrollment, According to CSC Survey 2Health News:Health Plan Executives Foresee Continued Decline in Small Business Enrollment, According to CSC Survey 3Health News:Life Sciences Discovery awards health research program grants 2Health News:Life Sciences Discovery awards health research program grants 3Health News:Life Sciences Discovery awards health research program grants 4Health News:Life Sciences Discovery awards health research program grants 5Health News:VirtualHealth Technologies, Inc. Appoints Former DEA Assistant Administrator to its Advisory Board 2Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 2Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 3Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 4Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 5Health News:Cerebrio, LLC, an Omnicom Group Company, and MedLink International Undertake an Exclusive Development and Marketing Arrangement 2
(Date:9/30/2014)...  Decision Resources Group finds that the Asia Pacific ... China , India , ... through 2023. Dental implant procedure volumes will grow as physicians are ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe ... destination , today announced that it now offers the ... AirSense CPAPs are the first sleep apnea therapy devices ... simple and easy to track and share real-time data ... effectiveness of their CPAP therapy.  In addition, the internal ...
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... agreement that allows Kessler Foundation and New Jersey ... biomedical research, education and patient care programs has ... and chief executive officer of Kessler Foundation and ... Jersey Health Foundation. "The experience of ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... Leading academic and industry specialists ... discuss the challenges that could see R&D grind to a ... Selecting and screening the correct polymorphs and ensuring ... effective way has never been more vital. According to George ...
... Ontario, Canada, Oct. 27, 2011 Valeant Pharmaceuticals International, Inc. ... of 8,523,517 additional common shares of Afexa Life Sciences Inc. ... of the offer by its wholly-owned subsidiary 1625907 Alberta Ltd. ... of Afexa. As all of the conditions to the offer ...
Cached Medicine Technology:Pharma Industry Unites With Academia to Tackle Ongoing Problem 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: